Dr. Patrick Frankham, Pivot’s CEO, comments, “Thrudermic is Pivot’s fourth disruptive formulation and delivery platform for cannabinoids . We are thrilled that Dr. Borovsky and Dr. Lurya have agreed to join us to develop and commercialize therapeutic bio-cannabis products. They are highly experienced … Read More
The post Breaking News: Pivot Pharma Acquires Thrudermic, LLC appeared first on Dagga Magazine.